Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.
Priority review is granted to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis, or prevention of serious ...
Zacks.com on MSN5d
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority TagSanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...
GlobalData on MSN5d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoidAs Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback